RUNX Inhibitors via Pyrrole-Imidazole Polyamides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional small-molecule compounds that inhibit protein-protein binding, such as between RUNX1 and CBFβ, have limited nuclear penetration and are prone to resistance due to protein mutations, necessitating novel antitumor agents that can suppress tumor protein expression at a transcriptional level.
Innovation Solution
Development of RUNX inhibitors that target RUNX binding sites on genomic DNA, specifically using pyrrole-imidazole polyamides conjugated with alkylating agents like chlorambucil to down-regulate target gene expressions, effectively inhibiting all members of the RUNX family.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional small-molecule compounds are used to inhibit protein-protein binding between RUNX1 and CBFβ, then the binding inhibition effect is achieved, but the nuclear penetration ability is limited and resistance occurs due to protein mutations
Solution Approach 1:
The patent introduces pyrrole-imidazole polyamides as intermediary molecules that specifically bind to RUNX binding sites on genomic DNA. These polyamides act as mediators between the therapeutic agent and the target gene, preventing RUNX family members from binding to DNA without requiring direct inhibition of protein-protein interactions. This intermediary approach enables effective nuclear delivery and transcriptional suppression while avoiding resistance to protein mutation
Solution Approach 2:
The patent employs chemical conjugation of alkylating agents (such as chlorambucil) to pyrrole-imidazole polyamides, fundamentally changing the chemical and functional parameters of the therapeutic molecule. This conjugation enhances the polyamide's ability to bind to RUNX binding sites on DNA and provides alkylating activity to further suppress target gene expression, thereby overcoming the limitations of conventional small-molecule inhibitors
2Reliability
If conventional small-molecule compounds inhibit protein-protein binding, then the binding inhibition effect is achieved, but resistance occurs due to protein mutations
Solution Approach 1:
The patent introduces pyrrole-imidazole polyamides as intermediary molecules that specifically bind to RUNX binding sites on genomic DNA. These polyamides act as mediators between the therapeutic agent and the target gene, preventing RUNX family members from binding to DNA without requiring direct inhibition of protein-protein interactions. This intermediary approach enables effective nuclear delivery and transcriptional suppression while avoiding resistance to protein mutation
Solution Approach 2:
Instead of directly inhibiting the protein-protein binding between RUNX1 and CBFβ as conventional approaches do, the patent inverts the strategy by targeting the DNA binding site of RUNX family members. The pyrrole-imidazole polyamides bind to the RUNX consensus sequence on genomic DNA, preventing RUNX proteins from accessing their target genes. This inverted approach targets the DNA interaction interface rather than the protein-protein interface, thereby overcoming resistance to protein mutation
3Reliability
If pyrrole-imidazole polyamides are conjugated with alkylating agents, then the sequence-specific genomic DNA-binding capacity is enhanced, but the molecular weight increases
Solution Approach 1:
The patent employs chemical conjugation of alkylating agents (such as chlorambucil) to pyrrole-imidazole polyamides, fundamentally changing the chemical and functional parameters of the therapeutic molecule. This conjugation enhances the polyamide's ability to bind to RUNX binding sites on DNA and provides alkylating activity to further suppress target gene expression, thereby overcoming the limitations of conventional small-molecule inhibitors
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RUNX inhibitors demonstrate in vivo inhibition effects on AML cells and diverse tumors, including those resistant to other molecular target drugs, offering a potent antitumor effect and potential use as an antiallergic agent.
Implementation Method 1
pyrrole-imidazole polyamides are synthetic oligomers that recognize specific DNA sequences located within the minor groove by virtue of their pyrrole (P) and imidazole (I) pairs interlocked by a hairpin linkage
Implementation Method 2
Pairing "P" opposite "I" in PI polyamides recognizes a C-G base pair; paring P opposite P recognizes an A-T or T-A base pair; and paring "I" opposite "P" recognizes a G-C pair
Implementation Method 3
conjugated the nitrogen mustard alkylating agent chlorambucil to PI polyamides; and showed that they have a much stronger sequence-specific genomic DNA-binding capacity
Data Source
AI summary
Provided are a RUNX inhibitor which binds to a RUNX-binding sequence on DNA and thus inhibits the binding of a RUNX family member to the sequence; an antitumor agent comprising the RUNX inhibitor; and an antiallergic agent comprising the RUNX inhibitor.